The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

圣莫尼卡/费城 - 吉利德科学公司 (NASDAQ: GILD )旗下的Kite公司，作为生物技术行业的重要参与者，市值达1478亿美元，周三宣布已达成最终协议，将以3.5亿美元现金收购私人持有的Interius ...

8月21日，吉利德科学宣布以3.5亿美元全资收购CAR-T疗法开发公司Interius ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Kite unit will acquire Interius BioTherapeutics for $350M, strengthening its position with in vivo CAR therapeutics. Kite said that Interius' platform "enables the generation of CAR T-cells directly ...

A University of Pennsylvania spinout that is developing a faster and cheaper way to modify immune cells to fight cancer will be sold to a unit of Gilead Sciences Inc. for $350 million under an ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Kite, a Gilead Company, has agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics.